RedHill adds two more manufacturing partners, both U.S.-based, for large-scale manufacturing of opaganib, in preparation for potential emergency use applications as early as Q1/2021 The new collaborations follow recently announced collaborations with European and Canadian manufacturers U.S. ...
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 23, 2020 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it will present and participate at the following virtual conferences in December: Evercore ISI 3 rd ...
RHB-204 is being evaluated as a first-line, stand-alone, oral treatment for pulmonary nontuberculous mycobacteria (NTM) disease - a rare condition with no FDA-approved first-line therapy The Phase 3 study is expected to recruit up to 125 patients across approximately 40 U.S. ...
Pre-scheduled independent Data and Safety Monitoring Board (DSMB) unanimously recommends continuation of the global Phase 2/3 study of orally administered opaganib in severe COVID-19 pneumonia Enrollment in the 270-patient global Phase 2/3 COVID-19 study with opaganib is more than 50% complete ...
FDA clears IND application for Phase 2/3 study with RedHill's second novel COVID-19 candidate, RHB-107 (upamostat), an orally administered novel serine protease inhibitor, with demonstrated antiviral and potential tissue-protective effects The Phase 2/3 study is designed to evaluate ...
Enrollment completed in the U.S. Phase 2 study evaluating opaganib's safety and initial efficacy signal in 40 hospitalized patients with severe COVID-19 pneumonia A parallel global Phase 2/3 study with orally administered opaganib for severe COVID-19 is approximately 50% enrolled - on track to ...
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that Mr. Guy Goldberg , RedHill’s Chief Business Officer, will present a corporate overview and host ...
Q3/2020 net revenues of approximately $21 million , with gross profit of $10.6 million , or approximately 51% , up from $6.7 million and approximately 32% in Q2/2020 -- Strong growth for Talicia ® with approximately 300 % quarter- over -quarter prescription growth and rapid expansion of the ...
TEL AVIV, Israel and RALEIGH, N.C. , Nov. 05, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it will report its third-quarter 2020 financial results and business highlights on Thursday, ...
Notice of Allowance received for combination of RedHill’s novel orally-administered investigational drugs, opaganib and RHB-107, for treatment of solid tumor cancers; patent expected to extend IP protection until 2036 -- Combination of opaganib and RHB-107 demonstrated potent antitumor effect and ...